Offstream
news

A trial of a plant-based COVID-19 vaccine conducted by GSK and Medicago shows an overall 71% efficacy against disease caused by the predominant SARS-CoV-2 variants of concern observed during most of 2021, and 75% efficacy specifically against disease caused by Delta. The study excludes the Omicron variant, which was not in circulation at the time of the clinical trials.
2021-12-7

The Medicines and Healthcare products Regulatory Agency approves GSK and Vir Biotechnology's sotrovimab antibody treatment, after a clinical trial found that the treatment reduced the risk of hospital admission and death by 79% in vulnerable adults if administered within five days of symptoms developing.
2021-12-2

The Health Ministry panel committee approve the usage of the single-dose monoclonal antibody-based treatment sotrovimab developed by GlaxoSmithKline and Vir Biotechnology to treat mild and moderately-ill COVID-19 patients.
2021-09-27

Polish biotechnology company Mabion S.A. signs an agreement with Novavax to begin commercial-scale production trials for Novavax's future vaccine.
2021-03-3

GlaxoSmithKline and Sanofi begins new clinical trial of their protein-based vaccine candidate and aim to reach the final testing stage in the second quarter after setback last year.
2021-02-22

The government eases the restrictions on business operating hours outside of the Seoul Capital Area, allowing those businesses to operate until 10 p.m. local time amid a backlash over prolonged restrictions.
2021-02-6

GlaxoSmithKline and the German biotech firm CureVac sign an agreement worth 150 million euros ($180.7 million) to develop a vaccine to counter many variants of SARS-CoV-2. The vaccine, which is subject to regulatory approval, is expected to be introduced in 2022.
2021-02-3

The Japanese government extends an ongoing state of emergency in 10 prefectures, including Tokyo, which surpassed 100,000 cases yesterday.
2021-02-2

Sanofi and GlaxoSmithKline announce that their COVID-19 vaccine candidate will not be ready until the end of 2021.
2020-12-11

The United States government is expected to pay $2.1 billion to Sanofi and GlaxoSmithKline to try to develop and deliver 100 million doses of their potential COVID-19 vaccine.
2020-07-31